USFDAJun 1, 2026, 07:02 AM
Kamada Gets FDA Approval for New Rabies Testing Lab
AI Summary
Kamada Ltd. announced FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory, which is the gold standard for measuring rabies-neutralizing antibodies. This state-of-the-art facility, also approved by Health Canada and the Israeli Ministry of Health, significantly expands Kamada's advanced testing capabilities for its leading Anti-Rabies products, KEDRAB® and KAMRAB®, which generated over $70 million in sales in 2025. The new lab is expected to enhance operational efficiencies and reinforce the company's commitment to quality and scientific excellence.
Key Highlights
- Kamada received FDA approval for its new in-house Rabies Virus Neutralization Testing Laboratory.
- The lab performs the Rapid Fluorescent Focus Inhibition Test (RFFIT), the gold standard for rabies antibodies.
- It expands advanced testing capabilities for KEDRAB® and KAMRAB® manufacturing.
- The facility is located in Beit Kama, Israel, and is one of a limited number globally.
- Prior to FDA, the lab was also approved by Health Canada and the Israeli Ministry of Health.
- KEDRAB and KAMRAB sales exceeded $70 million in 2025, representing a leading franchise.
- The new lab is expected to increase operational efficiencies and strengthen quality infrastructure.
Price Impact
More from KMDA